BAUDETTE, Minn., June 20, 2017 /PRNewswire/ -- ANI
Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the
launch of Diphenoxylate HCl and Atropine Sulfate Tablets,
2.5mg/0.025mg. The annual U.S. market for Diphenoxylate HCl
and Atropine Sulfate Tablets is approximately $56 million, per IMS Health. Prior to ANI's
launch there were two companies marketing a generic version of this
drug product.
Arthur S. Przybyl, ANI's
President and CEO stated, "This is the seventh product that ANI has
successfully re-commercialized from its portfolio of acquired
discontinued ANDA products. Through the end of the first
quarter of 2017, ANI had re-commercialized five of the 54 acquired
products. Since the launch of the first product in December 2014 through the end of the first
quarter of 2017, these five products have generated cumulative net
revenues of $22 million and
cumulative gross profit of $12
million to ANI. We are pleased with the results of
these launches and, while these products have been instrumental in
building our base business, the opportunity to re-commercialize
additional products from this acquired pipeline continues to
represent a substantial growth opportunity for ANI."
About Diphenoxylate HCl and Atropine Sulfate
Tablets
Diphenoxylate HCl and Atropine Sulfate Tablets are effective as
an adjunctive therapy in the management of diarrhea.
About ANI
ANI Pharmaceuticals, Inc. (the "Company" or "ANI") is an
integrated specialty pharmaceutical company developing,
manufacturing, and marketing branded and generic prescription
pharmaceuticals. The Company's targeted areas of product
development currently include narcotics, oncolytics (anti-cancers),
hormones and steroids, and complex formulations involving extended
release and combination products. For more information, please
visit our website www.anipharmaceuticals.com.
Forward-Looking Statements
To the extent any statements made in this release deal with
information that is not historical, these are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Such statements include, but are not limited
to, statements about price increases, the Company's future
operations, products financial position, operating results and
prospects , the Company's pipeline or potential markets therefor,
and other statements that are not historical in nature,
particularly those that utilize terminology such as "anticipates,"
"will," "expects," "plans," "potential," "future," "believes,"
"intends," "continue," other words of similar meaning, derivations
of such words and the use of future dates.
Uncertainties and risks may cause the Company's actual results
to be materially different than those expressed in or implied by
such forward-looking statements. Uncertainties and risks include,
but are not limited to, the risk that the Company may face with
respect to importing raw materials; increased competition;
acquisitions; contract manufacturing arrangements; delays or
failure in obtaining product approval from the U.S. Food and Drug
Administration; general business and economic conditions; market
trends; products development; regulatory and other approvals and
marketing.
More detailed information on these and additional factors that
could affect the Company's actual results are described in the
Company's filings with the Securities and Exchange Commission,
including its most recent annual report on Form 10-K and quarterly
reports on Form 10-Q, as well as its proxy statement. All
forward-looking statements in this news release speak only as of
the date of this news release and are based on the Company's
current beliefs, assumptions, and expectations. The Company
undertakes no obligation to update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise.
For more information about ANI, please contact:
Investor Relations
IR@anipharmaceuticals.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/ani-pharmaceuticals-announces-launch-of-diphenoxylate-hcl-and-atropine-sulfate-tablets-300476360.html
SOURCE ANI Pharmaceuticals, Inc.